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ABSTRACT:
Uterine  leiomyomas,  or  fibroids,  are  extremely  common  tumors.  Regardless  of 
their  benign  nature,  fibroids  can  cause  considerable  morbidity.  Women  with 
African ancestry have a threefold increased risk of developing uterine leiomyomas 
with a greater symptom severity when compared to white women. Recently, we 
demonstrated that exon 2 of the MED12 gene is somatically altered in up to 70 per 
cent of uterine leiomyomas in a series of Finnish (Caucasian) patients. To validate 
these results in other populations, we sequenced a set of 28 uterine leiomyomas for 
MED12 exon 2 mutations from 18 different Black African or Coloured South African 
patients. We observed 14 mutation positive lesions (50%). When corrected by tumor 
size, these results are very similar to those derived in the Finnish material. This study 
confirms a major role of MED12 in the genesis of leiomyomas, regardless of ethnicity.
INTRODUCTION
Uterine  leiomyomas,  also  known  as  fibroids,  are 
benign  tumors  for  which  the  lifetime  risk  in  women 
over the age of 45 has been estimated to exceed 60% 
[1].  Fibroids  arise  from  the  smooth  muscle  cells  of 
the  myometrium  and  can  cause  significant  morbidity, 
such as abnormal uterine bleeding, abdominal pain and 
discomfort, pregnancy complications and even infertility 
[2]. Fibroids are the most common cause for hysterectomy, 
and they have a considerable socio-economic impact [3-
4].
Uterine leiomyomas are monoclonal, oestrogen and 
progesterone dependent tumors, which occur in women 
of reproductive age, and typically regress with the onset 
of menopause. On the other hand, parity and use of oral 
contraceptives  have  been  suggested  to  protect  women 
from the development of fibroids [1]. It is also known 
that  uterine  leiomyomas  do  not  affect  all  ethnicities 
equally. Women with African ancestry have a threefold 
risk  of  developing  uterine  leiomyomas  compared  with 
white women [5], and Africans have also been reported to 
have an earlier age at onset with larger, more numerous, 
and more rapidly-growing fibroids [6-7]. In addition to 
ethnicity, other factors, such as family history, smoking, 
alcohol intake, hypertension and increased body weight 
have been proposed to increase the risk of developing 
uterine leiomyomas [6, 8-10].
We  recently  identified  various  somatic  mutations 
in exon 2 of the mediator complex subunit 12 (MED12) 
gene, in as many as 70% of the studied uterine leiomyomas 
obtained from patients of Finnish (Caucasian) origin [11]. 
The mutation hot spot affected an evolutionary conserved 
region of the MED12 protein, and according to our results, 
large fibroids tended to have slightly fewer mutations than 
small fibroids. MED12 is part of the 26-subunit Mediator 
complex which is thought to regulate global as well as 
gene-specific transcription by bridging distant regulatory 
DNA  elements  to  the  RNA  polymerase  II  initiation 
complex [12]. 
The aim of this study was to investigate the frequency 
of MED12 exon 2 mutations in uterine leiomyomas of 
South  African  patients  to  confirm  that  MED12  has  a 
major role in the genesis of this tumor type in populations Oncotarget 2011; 2:  966 - 969 967 www.impactjournals.com/oncotarget
other than Finns. Thus, we screened a total of 28 uterine 
fibroids from 18 individual patients for these mutations.
RESULTS
We sequenced a set of 28 uterine leiomyomas from 
18 South African patients. Fourteen leiomyomas (50%) 
harbored a mutation in MED12 exon 2 (Table 1). Eight of 
these mutations were located in codon 44. In addition, two 
fibroids (7%) displayed a missense mutation in codon 36 
and one fibroid (3.6%) in codon 43. We also observed two 
(7%)  exonic  insertion-deletion  type  mutations  and  one 
somatic intronic T to A mutation (3.6%) eight base pairs 
upstream of the splice acceptor site of exon 2. All three 
mutations are predicted to result in an in-frame transcript. 
The somatic nature of the mutations was verified in all 
cases where normal tissue DNA was available (nine). Nine 
patients did not have any mutations in MED12 exon 2.
The difference between the frequency of mutation 
positive fibroids in women with mixed ancestry (Coloured) 
and  Black  South  African  women  was  statistically 
significant when compared with the frequency of mutation 
positive lesions in Finnish (Caucasian) women (p-value 
= 0.045) [11]. However, if corrected by tumor size, the 
results in the two series were very similar (p-value = 0.69).
DISCUSSION
To  our  knowledge,  this  is  the  first  description  of 
MED12 exon 2 mutation analysis in uterine leiomyomas 
from other than white women. In this study, a set of 28 
uterine leiomyomas from 18 South African patients was 
sequenced  for  MED12  exon  2  mutations  to  study  the 
role of MED12 in tumorigenesis of fibroids also in other 
populations  than  Finns. Altogether,  14  (50%)  mutation 
positive lesions were observed.
Ethnicity  is  an  important  epidemiological  risk 
factor for uterine leiomyomas in the general population. 
The effect of race on incidence and severity of fibroids 
is particularly significant. Several studies have reported 
a higher incidence of fibroids among Black women than 
other  racial  and  ethnic  groups  including  Caucasian, 
Hispanic, and Asian women [6, 10, 13]. Moreover, Black 
women tend to have more severe disease than Caucasian 
women,  including  an  earlier  age  at  diagnosis  and  at 
hysterectomy,  with  larger,  more  numerous,  and  more 
rapidly growing fibroids [6-7, 13]. 
The reasons for ethnic variation in uterine leiomyoma 
Patient
Age at
Diagnosis Ethnicity Number of 
Fibroids Fibroid Size Status of  MED12exon 2  Myometrium
FG106 50 Black South African 3 FG106_1 Fundal 20 x 10 cm c.130G>A, p.G44S x
FG106_2 Anterior 15 x 15 cm c.100-8T>A, p.E33_D34insPQ
FG107 48 Coloured Multiple FG107_1 Posterior 3.7 x 4.0 cm c.107T>G, p.L36R x
FG108 41 Coloured Not reported FG108_1 4.4 x 4.2 cm wt x
FG108_2 2.5 x 3.3 cm c.131G>A, p.G44D
FG108_3 Not reported c.149_163del15, p.A50_D54del
FG109 46 Coloured Multiple FG109_1 Not reported wt x
FG109_2 Not reported wt
FG141 27 Black South African 15 FG141_1 Fundal no size c.130G>C, p.G44R
FG141_3 Lateral no size c.131G>A, p.G44D
FG142 59 Black South African Multiple FG142_2 Lateral no size c.107T>G, p.L36R x
FG146 39 Coloured 1 FG146_1 7.0 x 7.1 cm wt x
FG147 30 Coloured 2 FG147_1 Anterior 6.7 x 6.7cm wt
FG147_2 Posterior no size c.130G>T, p.G44C
FG149 48 Coloured 2 FG149_1 1.3 x 1.3 cm wt x
FG150 47 Coloured 2 FG150_1 Anterior 4.3 x 4.1 cm wt x
FG150_2 Posterior 4.5 x 5.0 cm wt
FG151 39 Coloured 2 FG151_1 Anterior no size wt
FG151_2 Posterior no size wt
FG152 41 Coloured 2 FG152_1 Anterior 7.3 x 5.9 cm c.131G>C, p.G44A x
FG152_2 Posterior 11.0 x 7.5 cm c.131G>A, p.G44D
FG153 50 Coloured 2 FG153_1 Anterior no size c.128A>C, p.Q43P
FG154 45 Black South African 1 FG154_1 Inferior 5.0 x 4.5 cm wt x
FG155 33 Coloured Multiple FG155_1 Lateral no size c.122_148del27, p.V41_P49 x
FG155_2 Lateral no size c.131G>A, p.G44D
FG157 32 Black South African Multiple FG157_1 Not reported wt x
FG166 48 Coloured Multiple FG166_1 Anterior no size wt x
FG169 41 Black South African 2 FG169_1 Posterior 17.8 x 11.5 cm wt x
Table 1: Patient information and MED12 exon 2 mutation status of the studied fibroids.Oncotarget 2011; 2:  966 - 969 968 www.impactjournals.com/oncotarget
occurrence  are  unknown.  Various  possible  causes  for 
higher prevalence and greater symptom severity among 
Black  women  have  been  proposed.  For  example,  the 
differences may be due to genes that confer increased risk 
for poor outcome. Uterine leiomyomas are hormonally 
responsive tumors, and for instance, Black women have 
been reported to have a higher prevalence of oestrogen 
receptor-α PP variant than white women [14]. The variant 
has  been  associated  with  an  increased  risk  of  uterine 
leiomyomas in both ethnicities.
Our  studies  demonstrate  that  fibroids  from  both 
Caucasians  as  well  as  women  with  African  descent 
frequently harbor mutations in MED12 exon 2. The South 
African  series  displayed  significantly  fewer  mutation-
positive  lesions  than  the  previously  published  Finnish 
series. However, the tumors in the South African series 
tended to be larger, and because the results in the Finnish 
series  had  indicated  an  inverse  correlation  between 
MED12 mutations and tumor size, we analyzed the results 
after correction of this tumor characteristic. Indeed, after 
this correction the results were very similar. While further 
work remains to be done to clarify the reasons behind the 
observed differences, this study confirms a major role of 
MED12 in the tumorigenesis of leiomyomas, regardless 
of ethnicity.
MATERIALS AND METHODS
Patient Material
DNA of 28 uterine leiomyoma and 14 myometrium 
samples was obtained from the Department of Obstetrics 
and Gynaecology, Faculty of Health Sciences, University 
of Cape Town, South Africa. DNA had been extracted 
from fresh frozen tissue samples. Altogether 18 individual 
patients were included to this study and from each patient 
1-3 uterine leiomyomas were examined (Table 1). The 
patient  series  comprised  of  twelve  women  with  mixed 
ancestry (Coloured) and six Black South African women. 
This study was approved by the local Human Research 
Ethics Committee (REF: 008/1995 and REF: 433/2011).
Amplification of MED12 exon 2
Using  previously  reported  primer  sequences 
[11]  the  desired  DNA  fragment  was  amplified  with 
AmpliTaqGold®  enzyme  (Applied  Biosystems,  Foster 
City, CA, USA). The PCR products were purified using 
ExoSAP-IT  PCR  Purification  Kit  (USB  Corporation, 
Cleveland, OH, USA) and the sequencing reactions were 
performed  utilizing  the  Big  Dye  Terminator  v.3.1  Kit 
(Applied Biosystems, Foster City, CA, USA) according 
to  the  manufacturer’s  instructions.  Sequencing  was 
performed  on  an ABI3730 Automatic  DNA  Sequencer 
(Applied Biosystems at FIMM Genome and Technology 
Centre Finland). The sequence graphs were analyzed both 
manually  and  on  computer  with  Mutation  Surveyor  - 
program (Softgenetics, State College, PA, USA).
Statistical Analysis
Statistical analyses were performed using R software, 
version  2.14.0.  Differences  between  the  proportion  of 
mutation  positive  lesions  in  uterine  leiomyomas  with 
Finnish and South African patients were undertaken with 
Pearson’s χ2 test with 1 df. Also the differences between 
the frequency of large (at least 5.5cm diameter) mutation 
positive  lesions  in  the  South African  series  versus  the 
Finnish series, was evaluated with Fisher’s exact test.
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